Mon, Nov 9, 2026

FROG is the only setup in a clear long-term uptrend (price above SMA50/200, 52-week high within 2%). It broke above the 15-min opening range (102.30) on 6.9x median volume, closing at 103.11. While news is absent, the technical structure is strong: SMA20/50 at ~93.50 provide support, and the 20-day range (74-103.75) shows a steady climb. The stop at the opening range low (99.51) is 3.5% below entry, offering a tight risk profile with room to the next resistance near 108.00 (+4.7%).

24 sh @ $103.73 ($2,489.52) · stop $99.51 · target $108.00

NBIS broke above its 15-min opening range (134.80) on 7x median volume, closing at 135.70. It has a T1 anomaly spike (+2.99% in 5 min) and upcoming earnings (Benzinga report). However, the daily trend is down (price 16% below SMA50, RSI 36.9), making this a speculative bounce play. The stop at the opening range low (129.48) is 4.5% below entry. The target of 145.00 offers a 6.8% reward. Caution is warranted due to the lack of a confirmed catalyst beyond the price shock and the downtrend.

10 sh @ $136.96 ($1,369.60) · stop $129.47 · target $145.00

PRAX broke its 15-min opening range (281.67-289.50) on 5.4x volume, closing at 300.72. The move is backed by a T1 SEC filing (8-K) for results of operations, providing a fundamental catalyst for the surge. The price action shows strong momentum (+3.8% from OR high to close) with heavy volume support. The stop at the opening range low (281.67) is 6.3% below entry, offering a defined risk with significant upside to the next resistance level around 340. This is a high-conviction momentum play driven by a confirmed catalyst.

5 sh @ $304.11 ($1,520.53) · stop $281.67 · target $340.00

Long-term book: SPY at 15% of equity, held while its weekly close stays above its 200-day average: last week closed at 735.29, 0.67% vs its 200-day average 730.38.

1 sh @ $747.67 ($747.67)

Long-term leader: 12-month return 217.0% (skipping the last month), 21.8% above its 200-day average

2 sh @ $198.96 ($397.92) · stop $159.16 · target —

Long-term leader: 12-month return 160.8% (skipping the last month), 19.4% above its 200-day average

1 sh @ $352.24 ($352.24) · stop $281.79 · target —

Long-term leader: 12-month return 148.9% (skipping the last month), 25.9% above its 200-day average

1 sh @ $383.85 ($383.85) · stop $307.08 · target —

Long-term leader: 12-month return 107.8% (skipping the last month), 17.8% above its 200-day average

3 sh @ $143.74 ($431.23) · stop $114.99 · target —

Long-term leader: 12-month return 107.2% (skipping the last month), 21.7% above its 200-day average

2 sh @ $248.78 ($497.56) · stop $199.02 · target —

Trend core: 16.8% above a 50-day average 12.9% over the 200-day; 6-month 33% at 1.17% daily ATR (strength 28.2); 100% of its 52-week high

7 sh @ $195.33 ($1,367.31) · stop $190.75 · target —

Trend core: 21.2% above a 50-day average 34% over the 200-day; 6-month 82.8% at 5.23% daily ATR (strength 15.84); 97% of its 52-week high

2 sh @ $52.97 ($105.94) · stop $47.67 · target —

FROG is up ~3% with a strong breakout thesis holding above the 50-day SMA and VWAP. The position is profitable and the trend is intact. I am adjusting the stop to trail at the original risk distance (entry 103.73 - stop 99.51 = 4.22) to lock in gains if it reverses, while leaving the 108.00 target open to capture the rest of the move.

Price at 141.24 (+9.1% today) is approaching the 145.00 target. The position is up 3.14%, but has not yet moved up by its initial stop distance (7.49) to trigger the trailing stop rule. The session is closing; no new entries are allowed. I will hold through the close to see if the earnings anticipation sustains the move toward the target.

PRAX is up 12.67% today on a confirmed T1 SEC filing (8-K) and a major FDA Breakthrough Therapy designation for Elsunersen, plus an extended NDA review date for Relutrigine. The position is up 12.67% (39 pts), well past the initial stop distance of 31.77 pts, so the trailing stop is already set at 281.67. The thesis remains intact with strong fundamental catalysts and heavy volume support. No reason to sell or adjust exits; hold for the 340 target.

PRAX is up +7.88% today on strong T1/T2 catalysts: FDA Breakthrough Therapy designation for Elsunersen and an extended NDA review date for Relutrigine. The stock broke its 15-min opening range (281.67-289.50) on 5.4x volume and is currently trading at 300.10, well above the initial breakout level. The stop at 281.67 remains intact and provides a defined risk floor. The thesis (catalyst-driven momentum) is active and unbroken. No reason to exit or adjust yet.

PRAX is up 11.29% on strong FDA catalysts (Breakthrough Therapy designation for Elsunersen, Relutrigine NDA extension). The position is up 1.81% from entry, exceeding the original stop distance of 22.44 (304.11 - 281.67). Per rules, code trails the stop at that distance behind the current price (309.6 - 22.44 = 287.16) to lock in gains while letting the momentum run. Closing window is active; no new entries.

5 sh @ $310.78 · stop $287.16 · target $340.00

PRAX surged 15.85% on the back of an FDA Breakthrough Therapy designation for Elsunersen and an extended NDA review for Relutrigine (PDUFA Dec 27). The position is up 6.0% since entry with a trailing stop at 287.16, providing ample room for the momentum to run. No news breaks the trend, and the catalyst remains valid for a multi-day hold.

USO is a long-term book position held for months. The recent price shock (-0.50% in 1 min) and volume spike are anomalies without a fundamental catalyst (news absent). The position is down -1.04% today but remains well above its stop of 115.75 (approx -19.5%). The long-term thesis (12-month return 107.8%, 17.8% above 200-day average) is intact. No news breaks the trend. Intraday volatility does not justify exiting a long-term core holding. The closing window is active, preventing new entries, but existing positions are managed. No action needed.

Triggered by our news engine: USO -0.50% in 1 min (z -4.02 after removing SPY's move)

PRAX is up ~9.8% on a confirmed FDA Breakthrough Therapy designation. Price ($332.50) is well above the 50-day SMA ($291.48) and intraday VWAP ($310.78). The $340 target is close, but the catalyst (FDA) and analyst coverage (BTIG $826 PT) support further upside. The stop is currently at $304.81 (near entry); I will hold to let the trailing stop catch up to the strong trend, as the thesis remains intact. Invalidation would be a close below the 50-day SMA or a negative earnings surprise, neither of which has occurred yet.

GLXY broke out on earnings beat and CEO buy, but session is closed. Set watch for open to evaluate entry on pullback or breakout.

U is in the TREND CORE, which requires holding until the trailing stop or a close below the 50-day average. The price at 51.39 is well above the stop at 47.67. The recent -3.04% move is likely a reaction to the Silver Lake/PIF takeover rumors (T2 news, sev 84) and Q3 earnings context, but the trend remains intact. No news breaks the trend thesis. The closing window is active, so no new entries are possible anyway. We hold through the close.

LONG-TERM BOOK position. Price 389.67 is above stop 312.05. No new negative news. Hold.

Speculative bounce play. Price 141.29 is above stop 129.47. Target 145 is still in play. Hold.

Momentum play with SEC filing catalyst. Price 331.18 is above stop 310.39. Target 340 is in play. Hold.

LONG-TERM BOOK position. Price 252.76 is above stop 212.58. No new negative news. Hold.

TREND CORE position. Price 195.86 is above stop 190.75. Trend intact. Hold.

LONG-TERM BOOK position. Price 200.79 is above stop 160.43. No new negative news. Hold.

LONG-TERM BOOK position. Price 753.545 is above stop (none, but weekly close above 200-day avg). Hold.

LONG-TERM BOOK position. Price 142.45 is above stop 115.75. No new negative news. Hold.

LONG-TERM BOOK position. Price 356.22 is above stop 300.25. No new negative news. Hold.